EP0872552A1
(en)
*
|
1997-04-15 |
1998-10-21 |
Leadd B.V. |
A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
|
NL9101680A
(nl)
|
1991-10-04 |
1993-05-03 |
Tno |
Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
ES2224113T5
(es)
*
|
1994-02-16 |
2009-05-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
CA2156132A1
(en)
|
1994-08-16 |
1996-02-17 |
Abraham Bout |
Recombinant vectors derived from adenovirus for use in gene therapy
|
US5998205A
(en)
*
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
IL122614A0
(en)
|
1995-06-15 |
1998-08-16 |
Introgene Bv |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
EP0840797B1
(en)
|
1995-07-25 |
2014-09-03 |
Crucell Holland B.V. |
Methods and means for targeted gene delivery
|
DK0870044T3
(da)
*
|
1995-12-01 |
2004-08-02 |
Crucell Holland Bv |
Reguleret proteinekspression i stabilt transfekterede pattedyrsceller
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
US6110744A
(en)
|
1996-11-13 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Diminishing viral gene expression by promoter replacement
|
EP0938578B1
(en)
|
1996-12-05 |
2004-02-04 |
Crucell Holland B.V. |
Genetic modification of primate hemopoietic repopulating stem cells
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
JP2000509614A
(ja)
|
1997-03-04 |
2000-08-02 |
バクスター インターナショナル インコーポレイテッド |
アデノウイルスe1−相補性細胞系
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
FR2774699B1
(fr)
*
|
1997-11-17 |
2003-10-03 |
Rhone Poulenc Rorer Sa |
Methode de reduction des evenements de recombinaison homologue
|
WO1999027123A2
(en)
*
|
1997-11-26 |
1999-06-03 |
Board Of Regents, The University Of Texas System |
Modified sv40 viral vectors
|
CA2316414A1
(en)
|
1997-12-23 |
1999-07-01 |
Introgene B.V. |
Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
|
ATE344322T1
(de)
|
1998-02-13 |
2006-11-15 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0959136A1
(en)
|
1998-05-20 |
1999-11-24 |
Introgene B.V. |
Targeted delivery through a cationic amino acid transporter
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US6900049B2
(en)
*
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
EP1124976A1
(en)
*
|
1998-10-27 |
2001-08-22 |
Crucell Holland B.V. |
Improved aav vector production
|
IT1302403B1
(it)
*
|
1998-11-06 |
2000-09-05 |
Angeletti P Ist Richerche Bio |
Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
IL133032A
(en)
*
|
1998-11-20 |
2007-06-03 |
Introgene Bv |
Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
|
EP1016726A1
(en)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gene therapy to promote angiogenesis
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
EP1159438B1
(en)
*
|
1999-03-04 |
2008-07-30 |
Crucell Holland B.V. |
Use of adenoviral vector for synovial cell transduction
|
DK2163640T3
(da)
*
|
1999-04-15 |
2012-03-05 |
Crucell Holland Bv |
Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US7297680B2
(en)
*
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US7604960B2
(en)
*
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US20060099685A1
(en)
*
|
1999-04-15 |
2006-05-11 |
Yallop Christopher A |
Recombinant expression of factor VIII in human cells
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
EP1198559A1
(en)
*
|
1999-04-23 |
2002-04-24 |
Introgene B.V. |
Means and methods for nucleic acid transfer
|
AU777041B2
(en)
|
1999-05-17 |
2004-09-30 |
Crucell Holland B.V. |
Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
WO2001002607A1
(en)
|
1999-07-06 |
2001-01-11 |
Merck & Co., Inc. |
Adenovirus carrying gag gene hiv vaccine
|
EP1067190A1
(en)
*
|
1999-07-09 |
2001-01-10 |
Introgene B.V. |
Gene therapy for enhancing and/or inducing angiogenesis
|
EP1083229A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
CA2384439A1
(en)
*
|
1999-09-10 |
2001-03-22 |
Crucell Holland B.V. |
Modified adenoviral vectors for use in gene therapy
|
EP1083228A1
(en)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Modified adenoviral vectors for use in gene therapy
|
US6365394B1
(en)
*
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
US7115391B1
(en)
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
DE19955558C2
(de)
*
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7521220B2
(en)
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
*
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
AU1817401A
(en)
*
|
1999-12-14 |
2001-06-25 |
Genovo, Incorporated |
Methods and compositions for the manufacture of replication incompetent adenovirus
|
WO2001049325A2
(en)
*
|
2000-01-07 |
2001-07-12 |
Stichting Klinische Farmacologie Groningen |
Gene therapy to promote angiogenesis and/or the treatment of heart failure
|
US7132277B1
(en)
|
2000-01-31 |
2006-11-07 |
Merck & Co., Inc. |
Helper dependent vector system for gene therapy
|
AU4594401A
(en)
*
|
2000-03-24 |
2001-10-08 |
Calydon Inc |
Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
KR20010064682A
(ko)
*
|
2000-07-01 |
2001-07-11 |
김재호 |
E1b가 감쇠된 아데노바이러스를 이용한 cd/5-fc및 hsv-1 tk/gcv의 이중 자멸 유전자 시스템
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
US7223406B2
(en)
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
AU2001278981A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Tom F Lue |
Prevention and treatment of sexual arousal disorders
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
US6733993B2
(en)
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
WO2002024730A2
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
DE60138403D1
(de)
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
JP2004536572A
(ja)
*
|
2001-02-23 |
2004-12-09 |
セル・ジェネシス・インコーポレイテッド |
新規ベクター構築物
|
CA2441071C
(en)
|
2001-03-14 |
2010-06-22 |
Myriad Genetics, Inc. |
Tsg101-gag interaction and use thereof
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
US20030119771A1
(en)
*
|
2001-08-22 |
2003-06-26 |
Rompaey Luc Van |
Modulators of bone homeostasis identified in a high-throughput screen
|
ES2344253T3
(es)
|
2001-10-11 |
2010-08-23 |
MERCK SHARP & DOHME CORP. |
Vacuna contra el virus de la hepatitis c.
|
US7598362B2
(en)
|
2001-10-11 |
2009-10-06 |
Merck & Co., Inc. |
Hepatitis C virus vaccine
|
CA2465007C
(en)
|
2001-10-29 |
2012-01-17 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
ATE384785T1
(de)
*
|
2001-12-07 |
2008-02-15 |
Crucell Holland Bv |
Herstellung von viren, virusisolaten, und impfstoffen
|
NZ533332A
(en)
*
|
2001-12-17 |
2005-07-29 |
Crucell Holland B |
Efficient production of F(AB')2 fragments in mammalian cells
|
JP2005532036A
(ja)
|
2002-01-09 |
2005-10-27 |
理化学研究所 |
癌プロフィール
|
JP4488290B2
(ja)
*
|
2002-01-24 |
2010-06-23 |
ザ・スクリップス・リサーチ・インスティテュート |
効率的ターゲティングのためのファイバーシャフト変異
|
CA2476447A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Merck & Co., Inc. |
Method of determining adenovirus particle concentration
|
ES2871905T3
(es)
|
2002-03-01 |
2021-11-02 |
Immunomedics Inc |
Inmunoconjugado que comprende anticuerpos de RS7 humanizados
|
WO2003085138A1
(en)
*
|
2002-03-29 |
2003-10-16 |
Merck & Co., Inc. |
Methods of virus production
|
WO2003087348A1
(en)
*
|
2002-04-08 |
2003-10-23 |
The Johns Hopkins University |
Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
|
ES2335657T3
(es)
*
|
2002-04-25 |
2010-03-31 |
Crucell Holland B.V. |
Medios y metodos para la produccion de vectores de adenovirus.
|
ATE405663T1
(de)
*
|
2002-04-25 |
2008-09-15 |
Crucell Holland Bv |
Stabile adenovirale vektoren und methoden für deren vermehrung
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
WO2003106495A2
(en)
|
2002-06-14 |
2003-12-24 |
Immunomedics, Inc. |
MONOCLONAL ANTIBODY hPAM4
|
US7226755B1
(en)
*
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US7507568B2
(en)
*
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
EP1553983A2
(en)
*
|
2002-10-23 |
2005-07-20 |
Crucell Holland B.V. |
New settings for recombinant adenoviral-based vaccines
|
US20080153083A1
(en)
*
|
2003-10-23 |
2008-06-26 |
Crucell Holland B.V. |
Settings for recombinant adenoviral-based vaccines
|
US20050221493A1
(en)
*
|
2002-12-04 |
2005-10-06 |
Crucell Holland B.V. |
Recombinant virus production for the manufacturing of vaccines
|
WO2004055187A1
(en)
|
2002-12-17 |
2004-07-01 |
Crucell Holland B.V. |
Recombinant viral-based malaria vaccines
|
DE60312039T2
(de)
*
|
2002-12-20 |
2007-11-08 |
Chromagenics B.V. |
Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
|
ATE457716T1
(de)
|
2002-12-30 |
2010-03-15 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
WO2004092397A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Tmprss2 regulatory sequences and uses thereof
|
US20070212675A1
(en)
*
|
2003-04-15 |
2007-09-13 |
Novartis Ag |
Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof
|
DK1623023T3
(da)
*
|
2003-05-09 |
2009-03-02 |
Crucell Holland Bv |
Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
|
EP1626992B1
(en)
*
|
2003-05-23 |
2010-06-02 |
Crucell Holland B.V. |
Production of recombinant igm in per.c6 cells
|
JP4644663B2
(ja)
*
|
2003-06-03 |
2011-03-02 |
セル ジェネシス インコーポレイテッド |
ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
CA2528669A1
(en)
*
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US7026164B2
(en)
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
US20050186178A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Ennist David L. |
Oncolytic adenoviral vectors encoding GM-CSF
|
AU2004278517B2
(en)
*
|
2003-10-02 |
2010-04-01 |
Crucell Holland B.V. |
Packaging cells for recombinant adenovirus
|
US7482156B2
(en)
*
|
2003-10-15 |
2009-01-27 |
Cell Genesys, Inc. |
Hepatocellular carcinoma specific promoter and uses thereof
|
EP1528101A1
(en)
*
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
EP1687032B1
(en)
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
|
CA2880061C
(en)
|
2004-01-23 |
2018-03-13 |
Agostino Cirillo |
Chimpanzee adenovirus vaccine carriers
|
JP2007526455A
(ja)
*
|
2004-02-03 |
2007-09-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
|
ES2329607T3
(es)
*
|
2004-02-23 |
2009-11-27 |
Crucell Holland B.V. |
Metodos de purificacion de virus.
|
US7473418B2
(en)
*
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
CA2563396A1
(en)
|
2004-04-12 |
2005-11-24 |
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services |
Method of using adenoviral vectors to induce an immune response
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
CA2567741A1
(en)
*
|
2004-05-25 |
2006-03-30 |
Chimeracore, Inc. |
Self-assembling nanoparticle drug delivery system
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
WO2006039045A2
(en)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
WO2006031689A2
(en)
|
2004-09-13 |
2006-03-23 |
Genzyme Corporation |
Multimeric constructs
|
DK1807009T3
(da)
|
2004-10-05 |
2015-03-02 |
Genzyme Corp |
Trappeformet kanyle
|
US8563511B2
(en)
|
2004-10-06 |
2013-10-22 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
EP2377882A1
(en)
|
2004-10-28 |
2011-10-19 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Peripherally delivered glutamatic acid decarboxylase gene therapy for spinal cord injury pain
|
SI1809750T1
(sl)
*
|
2004-11-08 |
2012-08-31 |
Chromagenics Bv |
Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
|
BRPI0517380A
(pt)
|
2004-11-08 |
2008-10-07 |
Chromagenics Bv |
molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
|
US8039230B2
(en)
*
|
2004-11-08 |
2011-10-18 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US8999667B2
(en)
*
|
2004-11-08 |
2015-04-07 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US20060195935A1
(en)
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
JP4621743B2
(ja)
*
|
2004-12-13 |
2011-01-26 |
カンジ,インコーポレイテッド |
複製欠損アデノウイルスの産生のための細胞株
|
WO2006078853A2
(en)
|
2005-01-20 |
2006-07-27 |
University Of Rochester |
Thioredoxin interacting protein (txnip) as regulator of vascular function
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
SI2816118T1
(sl)
|
2005-05-31 |
2019-01-31 |
The Regents Of The University Of Colorado, A Body Corporate |
Metode za dostavo genov
|
EP1907858A4
(en)
*
|
2005-06-13 |
2009-04-08 |
Univ Michigan |
COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
CA2610919C
(en)
*
|
2005-06-17 |
2013-09-10 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Hepatitis c virus nucleic acid vaccine
|
CA2616221C
(en)
*
|
2005-07-22 |
2011-07-05 |
Crucell Holland B.V. |
Cell line for producing coronaviruses
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US8765146B2
(en)
*
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
CA2814598A1
(en)
|
2005-09-12 |
2007-03-22 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in prostate cancer
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
JP5129149B2
(ja)
*
|
2005-10-31 |
2013-01-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を処置および診断するための組成物および方法
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
EP1961065A4
(en)
|
2005-10-31 |
2009-11-11 |
Oncomed Pharm Inc |
COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
|
BRPI0618441B8
(pt)
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
EP1974044B1
(en)
*
|
2005-12-12 |
2011-01-26 |
CANJI, Inc. |
Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
JP2009526066A
(ja)
|
2006-02-09 |
2009-07-16 |
ジェンザイム・コーポレーション |
遅速性脳室内送達
|
WO2008121102A2
(en)
*
|
2006-02-21 |
2008-10-09 |
The Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
US7968700B2
(en)
*
|
2006-03-20 |
2011-06-28 |
Chromagenics B.V. |
Expression augmenting DNA fragments, use thereof, and methods for finding thereof
|
BRPI0710645A2
(pt)
|
2006-04-07 |
2012-03-20 |
The Procter & Gamble Company |
Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
|
ATE460922T1
(de)
*
|
2006-04-07 |
2010-04-15 |
Chimeros Inc |
Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
|
US8840882B2
(en)
*
|
2006-06-23 |
2014-09-23 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
WO2007150069A2
(en)
|
2006-06-23 |
2007-12-27 |
Myriad Genetics, Inc. |
Dpyd gene variants and use thereof
|
US7589212B2
(en)
*
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7795444B2
(en)
*
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
SI2041259T1
(sl)
|
2006-07-14 |
2016-04-29 |
Dpx Holdings B.V. |
Izboljšan postopek kultiviranja celic
|
JP2009543868A
(ja)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
癌治療に関する方法および組成物
|
WO2008030605A2
(en)
*
|
2006-09-08 |
2008-03-13 |
The Regents Of The University Of Michigan |
Herv group ii viruses in lymphoma and cancer
|
US20080248060A1
(en)
*
|
2007-01-09 |
2008-10-09 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US11371194B2
(en)
*
|
2007-01-19 |
2022-06-28 |
Brock Usa, Llc |
Base for turf system
|
EP2106439B1
(en)
*
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
DE602008004476D1
(de)
*
|
2007-03-09 |
2011-02-24 |
Vectorlogics Inc |
Zellen für adenovirusvektor- und proteinherstellung
|
US20090226525A1
(en)
*
|
2007-04-09 |
2009-09-10 |
Chimeros Inc. |
Self-assembling nanoparticle drug delivery system
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
CA2692441C
(en)
|
2007-07-06 |
2020-01-21 |
The Regents Of The University Of Michigan |
Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
|
AU2008289172B2
(en)
|
2007-08-16 |
2013-01-17 |
Metabolon, Inc. |
Metabolomic profiling of prostate cancer
|
DE102007041655A1
(de)
|
2007-09-03 |
2009-03-05 |
Medicyte Gmbh |
Vermehrung von primären Zellen und deren Verwendung
|
US8697062B2
(en)
*
|
2007-10-08 |
2014-04-15 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapeutics
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
Ferring Int Ct Sa |
藥學製劑
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
JP5684122B2
(ja)
*
|
2008-07-15 |
2015-03-11 |
クルセル ホランド ベー ヴェー |
Per.c6細胞の培養およびそれからの生成物の生産のための拡張可能なプロセス
|
WO2010033722A2
(en)
|
2008-09-17 |
2010-03-25 |
Isogenis, Inc. |
Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
|
NZ592338A
(en)
|
2008-09-26 |
2012-11-30 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
JP2012504423A
(ja)
|
2008-10-01 |
2012-02-23 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
治療用リボヌクレアーゼ
|
US20110184154A1
(en)
*
|
2008-10-17 |
2011-07-28 |
Percivia Llc |
Cell broth clarification and host cell protein removal
|
PL2350268T3
(pl)
*
|
2008-11-03 |
2015-05-29 |
Crucell Holland Bv |
Sposób wytwarzania wektorów adenowirusowych
|
BRPI1004572A2
(pt)
|
2009-01-09 |
2016-04-05 |
Univ Michigan |
"fusões genéticas recorrentes em câncer
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
EP2382474B1
(en)
|
2009-01-20 |
2015-03-04 |
Transgene SA |
Soluble icam-1 as biomarker for prediction of therapeutic response
|
US8772238B2
(en)
|
2009-03-18 |
2014-07-08 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
|
SG2014014021A
(en)
|
2009-03-24 |
2014-07-30 |
Transgene Sa |
Biomarker for monitoring patients
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
NZ594896A
(en)
|
2009-04-17 |
2013-07-26 |
Transgene Sa |
Biomarker for monitoring patients
|
ES2559007T3
(es)
|
2009-04-23 |
2016-02-10 |
Crucell Holland B.V. |
Alfa1 antitripsina humana recombinante
|
JP5917394B2
(ja)
|
2009-06-10 |
2016-05-11 |
ニューヨーク・ユニバーシティ |
病理学的タウタンパク質の免疫学的標的化方法
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
MY160399A
(en)
|
2009-07-06 |
2017-03-15 |
Aerpio Therapeutics Inc |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
EP2451935A2
(en)
|
2009-07-08 |
2012-05-16 |
Glycotope GmbH |
Perfusion bioreactor
|
CA2767458A1
(en)
|
2009-07-10 |
2011-01-13 |
Bruce Acres |
Biomarker for selecting patients and related methods
|
SG177655A1
(en)
|
2009-07-16 |
2012-02-28 |
Crucell Holland Bv |
Production of polio virus at high titers for vaccine production
|
KR20120052352A
(ko)
|
2009-08-07 |
2012-05-23 |
트랜스진 에스.에이. |
Hbv 감염을 치료하는 조성물
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
ES2445713T3
(es)
|
2009-10-15 |
2014-03-04 |
Crucell Holland B.V. |
Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
|
WO2011045378A1
(en)
|
2009-10-15 |
2011-04-21 |
Crucell Holland B.V. |
Method for the purification of adenovirus particles
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
WO2011057248A2
(en)
|
2009-11-09 |
2011-05-12 |
Genvec, Inc. |
Simian adenovirus and methods of use
|
CA2785594C
(en)
|
2010-01-08 |
2018-04-17 |
Profibrix Bv |
Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
NZ601424A
(en)
|
2010-02-15 |
2014-07-25 |
Crucell Holland Bv |
Method for the production of ad26 adenoviral vectors
|
WO2011116209A2
(en)
*
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
CN102892429B
(zh)
|
2010-03-17 |
2016-08-31 |
康奈尔大学 |
基于被破坏的腺病毒的抗滥用药物疫苗
|
TW201823463A
(zh)
|
2010-03-23 |
2018-07-01 |
美商英翠克頌公司 |
條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途
|
CA2794674A1
(en)
|
2010-04-01 |
2011-10-06 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
DE102010041958A1
(de)
|
2010-10-04 |
2012-04-05 |
Medicyte Gmbh |
Geeignete Hepatozyten für in-vitro Genotoxitätstests
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
US8920813B2
(en)
|
2010-12-20 |
2014-12-30 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
EP2658567A4
(en)
|
2010-12-28 |
2014-09-24 |
Univ Rochester |
METHOD FOR MODIFYING INSULIN SIGNAL TRANSMISSION BY BILIVERDINREDUCTASE (BVR) AND BVR-DERIVED PEPTIDES
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
EP3450568A3
(en)
|
2011-03-04 |
2019-04-24 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
LT2729173T
(lt)
|
2011-07-06 |
2016-10-10 |
Sykehuset Sorlandet Hf |
Egfr taikinių terapija
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Hbv聚合酶突變體
|
WO2013036875A1
(en)
|
2011-09-07 |
2013-03-14 |
Mount Sinai School Of Medicine |
Ceramidase and cell differentiation
|
CA2847888A1
(en)
|
2011-09-09 |
2013-03-14 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
TW201318637A
(zh)
|
2011-09-29 |
2013-05-16 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(一)
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
US9233153B2
(en)
|
2011-10-05 |
2016-01-12 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
WO2013052832A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vectors and methods of use
|
WO2013052859A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
IN2014DN03061A
(da)
|
2011-10-05 |
2015-05-15 |
Genvec Inc |
|
WO2013056240A1
(en)
|
2011-10-13 |
2013-04-18 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome and cancer
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
US9404090B2
(en)
|
2011-11-24 |
2016-08-02 |
Viromed Co., Ltd. |
Adenovirus producing novel cell line and the use thereof
|
US20150004144A1
(en)
|
2011-12-02 |
2015-01-01 |
The General Hospital Corporation |
Differentiation into brown adipocytes
|
ES2623259T3
(es)
|
2011-12-08 |
2017-07-10 |
Virovek, Inc. |
Vectores que albergan genes tóxicos, métodos y usos de los mismos
|
WO2013116591A1
(en)
|
2012-02-02 |
2013-08-08 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccine
|
CN107982548A
(zh)
|
2012-02-07 |
2018-05-04 |
全球生物疗法有限公司 |
核酸输送的区室化方法及其组合物和应用
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
SG11201405228VA
(en)
|
2012-03-12 |
2014-11-27 |
Crucell Holland Bv |
Batches of recombinant adenovirus with altered terminal ends
|
EP2827895B1
(en)
|
2012-03-22 |
2017-08-09 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
WO2013181128A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Modified serotype 28 adenoviral vectors
|
EP2855511B1
(en)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Herpes simplex virus vaccine
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
TWI638829B
(zh)
|
2012-07-10 |
2018-10-21 |
法商傳斯堅公司 |
分枝桿菌抗原疫苗
|
EP2880154B1
(en)
|
2012-08-03 |
2019-05-15 |
Sanofi Pasteur SA |
Production of infectious influenza viruses
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
EP2908853B1
(en)
|
2012-10-21 |
2018-12-05 |
University Of Rochester |
Thy1 (cd90) as a therapy to control adipose tissue accumulation
|
WO2014066328A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
SG11201503864TA
(en)
|
2012-11-16 |
2015-06-29 |
Beth Israel Hospital |
Recombinant adenoviruses and use thereof
|
BR112015013849A2
(pt)
|
2012-12-21 |
2017-07-11 |
Sykehuset Soerlandet Hf |
terapia direcionada a egfr de distúrbios neurológicos e dor
|
CA2899353A1
(en)
|
2013-02-04 |
2014-08-07 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a wnt pathway inhibitor
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
KR101606910B1
(ko)
|
2013-03-29 |
2016-04-04 |
충북보건과학대학교 산학협력단 |
아데노바이러스 벡터 생산용 a549 기반 세포주
|
MX2015014568A
(es)
|
2013-04-17 |
2016-12-02 |
Genzyme Corp |
Composiciones y metodos para tratar y prevenir la degeneracion macular.
|
EP2992112B1
(en)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
|
AP2015008815A0
(en)
|
2013-04-25 |
2015-10-31 |
Crucell Holland Bv |
Stabilized soluble prefusion rsv f polypeptides
|
EP3848044A1
(en)
|
2013-05-21 |
2021-07-14 |
President and Fellows of Harvard College |
Engineered heme-binding compositions and uses thereof
|
MY171210A
(en)
|
2013-06-17 |
2019-10-02 |
Janssen Vaccines & Prevention Bv |
Stabilized soluble pre-fusion rsv f polypeptides
|
ES2525768B1
(es)
*
|
2013-06-24 |
2015-10-07 |
Curaxis, S.L. |
Procedimiento para la producción de proteínas recombinantes glicosiladas.
|
CA2920261C
(en)
|
2013-08-08 |
2018-04-03 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
ES2711115T3
(es)
|
2013-09-19 |
2019-04-30 |
Janssen Vaccines & Prevention Bv |
Formulaciones de adenovirus mejoradas
|
JP6683604B2
(ja)
|
2013-09-30 |
2020-04-22 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
高密度粗製細胞培養回収物の清澄化のための方法
|
US10765731B2
(en)
|
2014-01-09 |
2020-09-08 |
Transgene Sa |
Fusion of heterooligomeric mycobacterial antigens
|
MX2016010215A
(es)
|
2014-02-06 |
2016-11-15 |
Genzyme Corp |
Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
|
EP2927685A1
(en)
|
2014-04-02 |
2015-10-07 |
Medicyte GmbH |
Suitable hepatocytes for in-vitro hepatitis tests
|
CA2955877A1
(en)
|
2014-07-24 |
2016-01-28 |
Janssen Vaccines & Prevention B.V. |
Process for the purification of poliovirus from cell cultures
|
US10046064B2
(en)
|
2014-09-07 |
2018-08-14 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
|
WO2016044707A1
(en)
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Compositions and methods for treating fibrosis
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
MY181175A
(en)
|
2014-11-04 |
2020-12-21 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv16 vaccines
|
US10345259B2
(en)
|
2015-02-19 |
2019-07-09 |
Janssen Vaccines & Prevention B.V. |
Method for quantification of virus particles using capillary zone electrophoresis
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
JP6887955B2
(ja)
|
2015-03-18 |
2021-06-16 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
組換え体発現系のアッセイ
|
SI3283634T1
(sl)
|
2015-04-14 |
2019-08-30 |
Janssen Vaccines & Prevention B.V. |
Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
|
WO2016168601A1
(en)
|
2015-04-17 |
2016-10-20 |
Khalid Shah |
Agents, systems and methods for treating cancer
|
CN107708718B
(zh)
|
2015-04-22 |
2022-01-11 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
EP3319634B1
(en)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
JP7189014B2
(ja)
|
2015-07-07 |
2022-12-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Rsvに対するワクチン
|
EA037295B1
(ru)
|
2015-08-20 |
2021-03-05 |
Янссен Вэксинс Энд Превеншн Б.В. |
Терапевтические вакцины против hpv18
|
JP6487604B2
(ja)
|
2015-10-06 |
2019-03-20 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
生物学的製剤のプラスチック誘起分解を防止する方法
|
WO2017074517A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Seracare Life Sciences, Inc. |
Adenovirus control virus
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
EP3371211A4
(en)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
|
JP7233928B2
(ja)
|
2016-04-05 |
2023-03-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Rsvに対するワクチン
|
DK3439672T3
(da)
|
2016-04-05 |
2021-02-15 |
Janssen Vaccines & Prevention Bv |
Stabiliserede opløselige præfusions-rsv-f-proteiner
|
WO2017189730A1
(en)
|
2016-04-26 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
CN109922829A
(zh)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
治疗性hpv疫苗组合
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
KR102573534B1
(ko)
|
2016-05-12 |
2023-08-31 |
얀센 백신스 앤드 프리벤션 비.브이. |
강력하고 균형 잡힌 양방향성 프로모터
|
ES2836598T3
(es)
|
2016-05-30 |
2021-06-25 |
Janssen Vaccines & Prevention Bv |
Proteínas F de RSV prefusión estabilizadas
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
US11091795B2
(en)
|
2016-07-11 |
2021-08-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
JP7229151B2
(ja)
|
2016-07-14 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Hpvワクチン
|
WO2018064523A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
KR20240015743A
(ko)
|
2017-01-07 |
2024-02-05 |
셀렉타 바이오사이언시즈, 인크. |
합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
|
US11241436B2
(en)
|
2017-01-25 |
2022-02-08 |
Northwestern University |
Autophagy inducers for treatment of CNS conditions
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
US11781116B2
(en)
|
2017-02-17 |
2023-10-10 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
WO2018194438A1
(ko)
|
2017-04-21 |
2018-10-25 |
(주)지뉴인텍 |
비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
Rsv感染に対する防御免疫を誘導するための方法及び組成物
|
SG11202001458SA
(en)
|
2017-09-15 |
2020-03-30 |
Janssen Vaccines & Prevention Bv |
Method for the safe induction of immunity against rsv
|
BR112020007157A2
(pt)
|
2017-10-13 |
2020-09-24 |
Selecta Biosciences, Inc. |
métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
|
MX2020004487A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
JP7438943B2
(ja)
|
2017-10-31 |
2024-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
WO2019086461A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
AU2018357912B2
(en)
|
2017-10-31 |
2023-11-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
EP3714043A4
(en)
|
2017-11-22 |
2021-08-11 |
The Regents of The University of Michigan |
COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
|
EP3723771A4
(en)
|
2017-12-11 |
2022-04-06 |
Beth Israel Deaconess Medical Center, Inc. |
RECOMBINANT ADENOVIRUS AND THEIR USES
|
JP7317047B2
(ja)
|
2018-01-23 |
2023-07-28 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
CN112135622A
(zh)
|
2018-03-06 |
2020-12-25 |
普莱西根股份有限公司 |
乙型肝炎疫苗及其用途
|
BR112021013507A2
(pt)
|
2019-01-10 |
2021-11-16 |
Janssen Biotech Inc |
Neoantígenos da próstata e seus usos
|
CA3137448A1
(en)
|
2019-04-25 |
2020-10-29 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
CN114126666A
(zh)
|
2019-04-28 |
2022-03-01 |
西莱克塔生物科技公司 |
用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
|
CN113950333A
(zh)
|
2019-05-15 |
2022-01-18 |
扬森疫苗与预防公司 |
使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
|
AU2020275455A1
(en)
|
2019-05-15 |
2021-12-09 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
US20220175908A1
(en)
|
2019-05-16 |
2022-06-09 |
Janssen Vaccines & Prevention B.V. |
Methods for Inducing a Safe Immune Response Against Polio Virus
|
JP2022534741A
(ja)
|
2019-05-28 |
2022-08-03 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
|
KR20220057578A
(ko)
|
2019-09-05 |
2022-05-09 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
US20220372515A1
(en)
|
2019-10-03 |
2022-11-24 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
AU2020361533A1
(en)
|
2019-10-08 |
2022-04-28 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
BR112022009598A2
(pt)
|
2019-11-18 |
2022-08-16 |
Janssen Biotech Inc |
Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
KR20230004739A
(ko)
|
2020-04-21 |
2023-01-06 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
인간화 항-인간 cd89 항체 및 이의 용도
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
US20230035403A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Method For Determining Responsiveness To Prostate Cancer Treatment
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
CA3189238A1
(en)
|
2020-07-13 |
2022-01-20 |
Transgene |
Treatment of immune depression
|
KR20230051221A
(ko)
|
2020-08-11 |
2023-04-17 |
머스큘로스켈레탈 트랜스플랜트 파운데이션 |
태반-유래 조성물로 심장 병태를 치료하는 방법
|
CN118139655A
(zh)
|
2021-08-13 |
2024-06-04 |
特里奥万斯控股公司 |
皮肤替代组合物及其产生和使用方法
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|